Remission induction and maintenance effect of probiotics on ulcerative colitis: A meta-analysis

被引:77
作者
Sang, Li-Xuan [1 ]
Chang, Bing [1 ]
Zhang, Wen-Liang [1 ]
Wu, Xiao-Mei [1 ]
Li, Xiao-Hang [1 ]
Jiang, Min [1 ]
机构
[1] China Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Shenyang 110001, Liaoning Prov, Peoples R China
关键词
Inflammatory bowel disease; Ulcerative colitis; Probiotics; Meta-analysis; BIFIDOBACTERIA-FERMENTED MILK; INFLAMMATORY-BOWEL-DISEASE; ESCHERICHIA-COLI; MAINTAINING REMISSION; CONTROLLED-TRIAL; NISSLE; 1917; CHILDREN; MESALAZINE; THERAPY;
D O I
10.3748/wjg.v16.i15.1908
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To evaluate the induction of remission and maintenance effects of probiotics for ulcerative colitis. METHODS: Information was retrieved from MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The induction of remission and promotion of maintenance were compared between probiotics treatment and non-probiotics treatment in ulcerative colitis. RESULTS: Thirteen randomized controlled studies met the selection criteria. Seven studies evaluated the remission rate, and eight studies estimated the recurrence rate; two studies evaluated both remission and recurrence rates. Compared with the non-probiotics group, the remission rate for ulcerative colitis patients who received probiotics was 1.35 (95% CI: 0.98-1.85). Compared with the placebo group, the remission rate of ulcerative colitis who received probiotics was 2.00 (95% CI: 1.35-2.96). During the course of treatment, in patients who received probiotics for less than 12 mo compared with the group treated by non-probiotics, the remission rate of ulcerative colitis was 1.36 (95% CI: 1.07-1.73). Compared with the non-probiotics group, the recurrence rate of ulcerative colitis patients who received probiotics was 0.69 (95% CI: 2.47-1.01). In the mild to moderate group who received probiotics, compared to the group who did not receive probiotics, the recurrence rate was 0.25 (95% CI: 0.12-0.51). The group who received Bfidobacterium bifidum treatment had a recurrence rate of 0.25 (95% CI: 0.12-0.50) compared with the non-probiotics group. CONCLUSION: Probiotic treatment was more effective than placebo in maintaining remission in ulcerative colitis. (C) 2010 Baishideng. All rights reserved.
引用
收藏
页码:1908 / 1915
页数:8
相关论文
共 24 条
[1]   Ecological control of the gastrointestinal tract. The role of probiotic flora [J].
Bengmark, S .
GUT, 1998, 42 (01) :2-7
[2]  
Cui HH, 2004, WORLD J GASTROENTERO, V10, P1521
[3]   Probiotics and the management of inflammatory bowel disease [J].
Fedorak, RN ;
Madsen, KL .
INFLAMMATORY BOWEL DISEASES, 2004, 10 (03) :286-299
[4]  
FULLER R, 1989, J APPL BACTERIOL, V66, P365
[5]   Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis:: a randomised controlled pilot trial [J].
Furrie, E ;
Macfarlane, S ;
Kennedy, A ;
Cummings, JH ;
Walsh, SV ;
O'Neil, DA ;
Macfarlane, GT .
GUT, 2005, 54 (02) :242-249
[6]   Probiotic Escherichia coli Nissle 1917 (EcN) for Successful Remission Maintenance of Ulcerative Colitis in Children and Adolescents: an Open-Label Pilot Study [J].
Henker, J. ;
Mueller, S. ;
Laass, M. W. ;
Schreiner, A. ;
Schulze, J. .
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2008, 46 (09) :874-875
[7]   Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis [J].
Ishikawa, H ;
Akedo, I ;
Umesaki, Y ;
Tanaka, R ;
Imaoka, A ;
Otani, T .
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 2003, 22 (01) :56-63
[8]   Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis [J].
Kato, K ;
Mizuno, S ;
Umesaki, Y ;
Ishii, Y ;
Sugitani, M ;
Imaoka, A ;
Otsuka, M ;
Hasunuma, O ;
Kurihara, R ;
Iwasaki, A ;
Arakawa, Y .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (10) :1133-1141
[9]   Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis [J].
Kruis, W ;
Schutz, E ;
Fric, P ;
Fixa, B ;
Judmaier, G ;
Stolte, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (05) :853-858
[10]   Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine [J].
Kruis, W ;
Fric, P ;
Pokrotnieks, J ;
Lukas, M ;
Fixa, B ;
Kascák, M ;
Kamm, MA ;
Weismueller, J ;
Beglinger, C ;
Stolte, M ;
Wolff, C ;
Schulze, J .
GUT, 2004, 53 (11) :1617-1623